Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia

Neoplasma

Volumn 58, Issue 3, 2011, Pages 256-262

  Voglova, J ^a   Muzik, J ^b   Faber, E ^c   Zackova, D ^e   Klamova, H ^d   Steinerova, K ^e   Michalovicova, Z ^e   Demitrovicova, L ^f   Cmunt, E ^g   Novakova, L ^d   Tothova, E ^h   Belohlavkova, P ^a   Mayer, J ^e   Indrak, K ^c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^e UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^f CANCER RESEARCH INSTITUTE   (Slovakia)

^g CHARLES UNIVERSITY   (Czech Republic)

^h L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

Author keywords

Chronic myeloid leukemia; Incidence; Second malignancy; Tyrosine kinase inhibitor

Indexed keywords

BUSULFAN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CZECH REPUBLIC; FEMALE; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RETROSPECTIVE STUDY; SECOND CANCER; SKIN CANCER; SLOVAKIA; DRUG ANTAGONISM; INCIDENCE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CZECH REPUBLIC; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SLOVAKIA;

EID: 79961120753     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_03_256     Document Type: Article

References (26)

1. O'BRIEN SG, GUILHOT F, GOLDMAN JM, HOCHHAUS A, HUGHES TP et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008; 112, 76. Abstract #186
2. CHROBÁK L, RADOCHOVÁ D, VÁCHA K. Occurrence of Cancer in Chronic Myeloid Leukemia Vnitr. lek 1977; 23: 773-780
3. The Italian cooperative study group on chronic myeloid leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92, 1541-1548
4. ROY L, GUILHOT J, MARTINEAU G, LARCHÉE R, GUILHOT F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005; 19: 1689-1692. doi:10.1038/sj.leu.2403874
5. PILOT PR, SABLINSKA K, OWEN S, HATFIELD A. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006; 20: 148. doi:10.1038/sj.leu.2404025
6. VERMA D, KANTARJIAN HM, RIOS MB, O'BRIEN S, AULT P et al: Malignancies occurring during therapy with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) and other hematologic malignancies. 2008 ASH meeting abstracts, Blood 2008;112: 740., #2125
7. GAMBACORTI-PASSERINI C, KIM D-W, MAHON FX, SAGLIO G, PANE F et al. Imatinib long term effects (ILTE) study: An independent, international study in CML patients. 2008 ASH meeting abstracts, Blood 2008; 112: 401., #1099
8. SWERDLOW SH, CAMP E, HARRIS NL, JAFFE ES, PILERI SA et al. WHO classification of tumours of haematopoietic and lymphoid tissue. IARC 4th edition. Lyon 2008, 32-37., ISBN-13, 978-92-832-2431-0
9. KLENER P, ABRAHÁMOVÁ J, FAIT V, MALIŠ J, MAT, JOVSKÝ et al. Klinická onkologie, Galén Praha 2002, kap. 7, Classification and staging of malignant diseases, 103-106, ISBN 80-7262-151-3
10. Cancer incidence in the Czech Republic 2001-2007, Institute of Health Information and Statistics of the Czech Republic, Prague 2001-2010.; Available at http://www.uzis.cz/download.php?ctg=10&search_name=Novotvary®ion=100&kind=1&mnu_id=5300
11. KAPLAN EL, MAIER P. Nonparametric estimation from incomplete observations. J. Amer. Statist. Assoc. 1958; 53: 457-481. doi:10.2307/2281868
12. MANTEL N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170
13. ESTEVE J, BENHAMOU E, RAYMOND L. Statistical methods in cancer research. Volume IV. Descriptive epidemiology. IARC Sci Publ. 1994; (128):1-302.
14. BRUSA G, ZUFFA E, HATTINGER CM, SERRA M, RE-MONDINI D et al. Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. Oncology Reports 2007; 18: 1427-1434
15. TRAVIS LB, RABKIN CS, BROWN LM, ALLAN JM, ALTER BP et al. Cancer survivorship - genetic susceptibil- ity and second primary cancers: Research strategies and recommendations. J Nat Cancer Inst 2006; 98: 15-25 misctextdoi:10.1093/jnci/djj001/misctext
16. FLAMM MJ, MURTY VS, RAO PH, NICHOLS GL. Coexistence of independent myelodysplastic and Philadelphia chromosome positive clones in a patient treated with hydroxyurea. Leukemia Research 2000; 26, 417-420 doi:10.1016/S0145-2126(01)00140-0
17. TEFFERI A. Is hydroxyurea leukemogenic in essential thrombocytemia? Blood 1998; 92, 1459-1460.
18. KOLB HJ, SOCIÉ G, DUELL T, VAN LINT MT, TICHELLI A et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Ann Intern Med 1999; 131: 738-744
19. ORCIUOLO E, FAZZI R, GALIMBERTI S, TESTI C, AZZARA A et al. Chronic myeloid leukemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy. Leukemia Research 2006; 30, 349-353. doi:10.1016/j.leukres.2005.07.011
20. CHANG H, SUTHERLAND R, NAYAR R, LI D, KAMELREID S et al. Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence -activated cell sorting. Cancer Genetics and Cytogenetics 2004; 152, 146-148. doi:10.1016/j.cancergencyto.2003.11.015
21. CRESCENZI B, SACCHI S, MARASCA R, TEMPERANI P, LA STARZA R et al. Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia. Leukemia 2002; 16: 955-956. doi:10.1038/ sj.leu.2402490
22. SALIM R, VANG L, LIN K, CLARK RE. Chronic lymphocytic leukemia developing in the course of chronic myeloid leukemia. Leuk Lymphoma 2002; 43, 2225-2227. PMid:12533052
23. ZHANG X, JI L, LIU S, WANG J. Ph-negative acute lymphocytic leukemia occurring after interferon therapy for Ph-positive chronic myeloid leukemia. Leukemia Research 2003; 27, 367-369. doi:10.1016/S0145-2126(02)00175-3
24. GARIPIDOU V, VAKALOPOULOU S., TZIOMALOS K. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate. The Oncologist 2005; 10: 457-458. doi:10.1634/theoncologist.106-457
25. DUŠEK L, MUŽÍK J, KUBÁSEK M, KOPTIKOVA J, BRABEC P et al. Epidemiology of Malignant Tumours in the Czech Republic [online]. Masaryk University, Czech Republic, [2005]., http://www.svod.cz. Version 7.0 [2007], ISSN 1802-8861.
26. QUINTAS-CARDAMA A, CORTES J. Molecular biology of bcr-abl1positive chronic myeloid leukemia. Blood 2009; 113: 1619-1630. doi:10.1182/blood-2008-03-144790